Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulse methylprednisolone in SLE.

R P Kimberly

    Clinics in Rheumatic Diseases
    |April 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    High-dose intravenous corticosteroids for non-renal systemic lupus erythematosus (SLE) lack sufficient evidence for optimal management. Further research is needed to clarify steroid protocols and long-term effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.

    Genes and immunity·2015
    Same author

    Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus.

    Genes and immunity·2014
    Same author

    GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region.

    Genes and immunity·2014
    Same author

    A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus.

    Genes and immunity·2012
    Same author

    Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis.

    Genes and immunity·2011
    Same author

    The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed.

    Genes and immunity·2011
    Same journal

    Metabolic and endocrine aspects of rheumatic disease.

    Clinics in rheumatic diseases·1986
    Same journal

    Muscle 'contractures' and the 'stiff-man' syndrome.

    Clinics in rheumatic diseases·1986
    Same journal

    Hypophosphatasia.

    Clinics in rheumatic diseases·1986
    Same journal

    Alkaptonuria.

    Clinics in rheumatic diseases·1986
    Same journal

    Diabetes mellitus and rheumatic disease.

    Clinics in rheumatic diseases·1986
    Same journal

    Musculoskeletal manifestations of primary hyperparathyroidism.

    Clinics in rheumatic diseases·1986
    See all related articles

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Systemic lupus erythematosus (SLE) management requires effective treatment strategies.
    • High-dose intravenous corticosteroids are used, but their efficacy in non-renal SLE is not well-established.
    • Optimal steroid preparation, dosage, and frequency remain unclear.

    Purpose of the Study:

    • To evaluate the effectiveness of high-dose intravenous corticosteroid treatment in non-renal SLE.
    • To address gaps in knowledge regarding steroid protocols and long-term outcomes.
    • To identify potential stratification variables for future clinical trials.

    Main Methods:

    • Review of existing literature on intravenous corticosteroid use in SLE.
    • Analysis of short-term complications and potential long-term effects like avascular necrosis.

    Related Experiment Videos

  • Discussion of the need for large randomized controlled trials (RCTs).

    • Main Results:

    • Short-term complications of high-dose intravenous corticosteroids appear minimal.
    • Long-term effects, such as avascular necrosis, are difficult to assess due to concurrent oral corticosteroid use.
    • Patients with recent glomerular filtration rate decline may benefit from IV-MP.

    Conclusions:

    • Insufficient evidence exists to confirm the superiority of high-dose intravenous corticosteroids for non-renal SLE.
    • Further research, including large RCTs with appropriate stratification, is crucial.
    • Outcome measures need refinement to accurately assess treatment benefits.